Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Loke, Y K, Ho, R, Smith, M, Wong, O, Sandhu, M, Sage, W and Singh, S (2013) Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. Journal of Clinical Pharmacy and Therapeutics, 38 (5). pp. 405-415. ISSN 1365-2710

Full text not available from this repository. (Request a copy)

Abstract

A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

Item Type: Article
Additional Information: © 2013 John Wiley & Sons Ltd.
Uncontrolled Keywords: 5-alpha reductase inhibitors,azasteroids,cardiovascular diseases,double-blind method,drug-related side effects and adverse reactions,humans,male,prostatic diseases,randomized controlled trials as topic,risk
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Aug 2014 10:50
Last Modified: 02 Apr 2020 00:33
URI: https://ueaeprints.uea.ac.uk/id/eprint/48927
DOI: 10.1111/jcpt.12080

Actions (login required)

View Item View Item